logo
  • About Initiator Pharma
    • Mission
    • Scientific and Clinical Advisory Board
    • Goals, strategy and business model
    • CEO Letter
    • History
  • Science
    • Pipeline
    • Pudafensine
      • Clinical programs
        • IPED2015 – Organic Erectile dysfunction
        • IPVU2025 – Neuropathic Pain/Vulvodynia
      • Preclinical program
        • IPFSD2023 – Female Sexual Dysfunction
    • IP2018
      • Clinical programs
        • IP2018 – Psychogenic Erectile dysfunction
      • Preclinical program
        • IPFSD2023 – Female Sexual Dysfunction
    • Therapeutic Areas
      • Erectile Dysfunction
      • Vulvodynia
      • Female Sexual Dysfunction
      • Depression
  • Governance
    • General Meetings
    • Management
    • Board of Directors
    • Auditing
    • Articles of Association
    • Remuneration and incentive program
  • Investors
    • Rights Issue 2025
    • Investment case
    • Financial Reports
    • The Share
    • Ownership Structure
    • Analyst and Media Coverage
    • Financial Calendar
    • Prospectuses
    • Press Releases
    • Subscribe
    • Certified Adviser
  • Media
    • Press Releases
    • Event Calendar
    • Subscribe
  • Contact
Loading..

Investors

Press releases

  • Regulatory November 21, 2025 English
    Correction: INITIATOR PHARMA: Q3 2025 REPORT
  • Regulatory November 21, 2025 English
    INITIATOR PHARMA: Q3 2025 REPORT
  • Non Regulatory November 3, 2025 English
    Initiator Pharma receives UK CTA approval to initiate Phase 2a study in vulvodynia
Older releases

Latest reports

  • Regulatory November 21, 2025 English
    Correction: INITIATOR PHARMA: Q3 2025 REPORT
  • Regulatory November 21, 2025 English
    INITIATOR PHARMA: Q3 2025 REPORT
  • Regulatory August 22, 2025 English
    INITIATOR PHARMA: Q2 2025 REPORT
All reports

Calendar

  • December 3, 2025
    Redeye Life Science Day
    Add to calendar
  • February 20, 2026
    Year-end report 2025 (Q4)
    Add to calendar
All events

Investor contact

IR Contact
IR Contact
Torgeir Vaage
[email protected]

Subscribe via e-mail

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of women in the US and Europe suffering from Vulvodynia 27 million
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
  • Investors
    • Rights Issue 2025
    • Investment case
    • Financial Reports
    • The Share
    • Ownership Structure
    • Analyst and Media Coverage
    • Financial Calendar
    • Prospectuses
    • Press Releases
    • Subscribe
    • Certified Adviser

Share

Read more
Initiator Pharma logo
About Initiator Pharma
  • Mission
  • Scientific and Clinical Advisory Board
  • Goals, strategy and business model
  • CEO Letter
  • History
Science
  • Pipeline
  • Pudafensine
    • Clinical programs
    • Preclinical program
  • IP2018
    • Clinical programs
    • Preclinical program
  • Therapeutic Areas
    • Erectile Dysfunction
    • Vulvodynia
    • Female Sexual Dysfunction
    • Depression
Governance
  • General Meetings
  • Management
  • Board of Directors
  • Auditing
  • Articles of Association
  • Remuneration and incentive program
Investors
  • Rights Issue 2025
  • Investment case
  • Financial Reports
  • The Share
  • Ownership Structure
  • Analyst and Media Coverage
  • Financial Calendar
  • Prospectuses
  • Press Releases
  • Subscribe
  • Certified Adviser
Media
  • Press Releases
  • Event Calendar
  • Subscribe
Contact
Edit

Share

Read more
  • Cookies
  • Privacy